UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging

Investigative radiology, 2000-08, Vol.35 (8), p.479-485

2000

Volltextzugriff (PDF)

Absence of developmental or reproductive toxicity in rats for MB-102, a fluorescent tracer agent for point-of-care measurement of glomerular filtration rate

Regulatory toxicology and pharmacology, 2022-06, Vol.131, p.105158-105158, Article 105158

2022

Volltextzugriff (PDF)

Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate

Regulatory toxicology and pharmacology, 2019-10, Vol.107, p.104417, Article 104417

2019

Volltextzugriff (PDF)

Evaluation of Developmental and Reproductive Toxicity in Rabbits for MB-102, a Fluorescent Tracer Agent Designed for Real-Time Measurement of Glomerular Filtration Rate

International journal of toxicology, 2022-09, Vol.41 (5), p.380-388

2022

Volltextzugriff (PDF)

Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate

Regulatory toxicology and pharmacology, 2015-06, Vol.72 (1), p.26-38

2015

Volltextzugriff (PDF)

18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer

Clinical cancer research, 2011-05, Vol.17 (10), p.3332-3340

2011

Volltextzugriff (PDF)

Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform

Journal of biomedical optics, 2001-04, Vol.6 (2), p.122-133

2001

Volltextzugriff (PDF)

Synthesis, In Vitro Receptor Binding, and In Vivo Evaluation of Fluorescein and Carbocyanine Peptide-Based Optical Contrast Agents

Journal of medicinal chemistry, 2002-05, Vol.45 (10), p.2003-2015

2002

Volltextzugriff (PDF)

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy

The Journal of nuclear medicine (1978), 2002-12, Vol.43 (12), p.1650-1656

2002

Volltextzugriff (PDF)

Novel Bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular Beacons to Tumors

Journal of medicinal chemistry, 2003-07, Vol.46 (15), p.3403-3411

2003

Volltextzugriff (PDF)

Stabilization of the Optical Tracer Agent Indocyanine Green Using Noncovalent Interactions

Photochemistry and photobiology, 2000-03, Vol.71 (3), p.347-350

2000

Volltextzugriff (PDF)

Dose enhancement through combining internalizing radiation and contrast media

Cancer biotherapy & radiopharmaceuticals, 2006-06, Vol.21 (3), p.173

2006

Volltextzugriff (PDF)

Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging

Investigative radiology, 2000-08, Vol.35 (8), p.479-485

2000

Volltextzugriff (PDF)

Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents

Cancer biotherapy & radiopharmaceuticals, 2006-06, Vol.21 (3), p.181

2006

Volltextzugriff (PDF)

Noninvasive Fluorescence Detection of Hepatic and Renal Function

Journal of Biomedical Optics, 1998-07, Vol.3 (3), p.340-345

1998

Volltextzugriff (PDF)

DOTA−d-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy

Bioconjugate chemistry, 2002-07, Vol.13 (4), p.721-728

2002

Volltextzugriff (PDF)

Toxicity and dosimetry of 177Lu‐DOTA‐Y3‐octreotate in a rat model

International journal of cancer, 2001-12, Vol.94 (6), p.873-877

2001

Volltextzugriff (PDF)

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

International journal of cancer, 2001-12, Vol.94 (6), p.873-877

2001

Volltextzugriff (PDF)

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy

Cancer research (Chicago, Ill.), 1998-02, Vol.58 (3), p.437-441

1998

Volltextzugriff (PDF)

Abstract 5244: Preclinical, real-time assessment of early pharmacodynamic effects for the IGF-1R/IR inhibitor OSI-906 by [18F]-FDG-PET

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5244-5244

2010

Volltextzugriff (PDF)

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy

Bioconjugate chemistry, 2002-07, Vol.13 (4), p.721-728

2002

Volltextzugriff (PDF)

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model

International journal of cancer, 2001-12, Vol.94 (6), p.873

2001

Volltextzugriff (PDF)

DOTA− d -Tyr 1 -Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy

Bioconjugate chemistry, 2002-07, Vol.13 (4), p.721-728

2002

Volltextzugriff (PDF)

Preclinical Comparison of 111In-Labeled DTPA- or DOTA-Bombesin Analogs for Receptor-Targeted Scintigraphy and Radionuclide Therapy

The Journal of nuclear medicine (1978), 2002-12, Vol.43 (12), p.1650-1656

2002

Volltextzugriff (PDF)

Radiotherapeutic efficacy of 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats

Nuclear medicine and biology, 2001-04, Vol.28 (3), p.327-334

2001

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Animals
(17)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Rats
(13)
Male
(8)
Pharmacology & Pharmacy
(8)
Female
(7)
Fluorescence
(7)
Biological And Medical Sciences
(6)
Humans
(6)
Medical Sciences
(6)
Pharmacology. Drug Treatments
(6)
Tissue Distribution
(6)
Biochemistry & Molecular Biology
(5)
Mice
(5)
Radiology, Nuclear Medicine & Medical Imaging
(5)
Biochemical Research Methods
(4)
Contrast Media. Radiopharmaceuticals
(4)
Neoplasms - Radiotherapy
(4)
Peptides
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging

Absence of developmental or reproductive toxicity in rats for MB-102, a fluorescent tracer agent for point-of-care measurement of glomerular filtration rate

Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate

Evaluation of Developmental and Reproductive Toxicity in Rabbits for MB-102, a Fluorescent Tracer Agent Designed for Real-Time Measurement of Glomerular Filtration Rate

Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate

18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer

Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform

Synthesis, In Vitro Receptor Binding, and In Vivo Evaluation of Fluorescein and Carbocyanine Peptide-Based Optical Contrast Agents

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy

Novel Bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular Beacons to Tumors

Stabilization of the Optical Tracer Agent Indocyanine Green Using Noncovalent Interactions

Dose enhancement through combining internalizing radiation and contrast media

Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging

Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents

Noninvasive Fluorescence Detection of Hepatic and Renal Function

DOTA−d-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy

Toxicity and dosimetry of 177Lu‐DOTA‐Y3‐octreotate in a rat model

Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy

Abstract 5244: Preclinical, real-time assessment of early pharmacodynamic effects for the IGF-1R/IR inhibitor OSI-906 by [18F]-FDG-PET

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model

DOTA− d -Tyr 1 -Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy

Preclinical Comparison of 111In-Labeled DTPA- or DOTA-Bombesin Analogs for Receptor-Targeted Scintigraphy and Radionuclide Therapy

Radiotherapeutic efficacy of 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats

Suchergebnisse filtern